--- title: "Avantor Kept at Hold as Analyst Trims Price Target to $9 Amid Execution and Market Recovery Risks" type: "News" locale: "en" url: "https://longbridge.com/en/news/284656417.md" description: "Avantor has been maintained at a Hold rating by analyst Daniel Brennan from TD Cowen, with a price target reduced to $9. The decision reflects a balance of improving company actions and ongoing risks, including execution challenges and competitive pressures. Despite modestly exceeding first-quarter expectations and management's confidence in a second-half recovery, the need for faster growth raises concerns. The VWR distribution and Bioscience & Medtech segments are still facing organic declines, prompting Brennan to await clearer evidence of sustainable growth before reassessing the stock." datetime: "2026-04-29T22:55:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284656417.md) - [en](https://longbridge.com/en/news/284656417.md) - [zh-HK](https://longbridge.com/zh-HK/news/284656417.md) --- # Avantor Kept at Hold as Analyst Trims Price Target to $9 Amid Execution and Market Recovery Risks Avantor, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Brennan from TD Cowen maintained a Hold rating on the stock and has a $9.00 price target. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Daniel Brennan has given his Hold rating due to a combination of factors that balance improving company actions with lingering risks. Avantor modestly exceeded first-quarter expectations and management signaled greater confidence in a second-half recovery, supported by turnaround initiatives, easing comparisons, and signs that key end markets may be bottoming, all against a valuation that already reflects considerable pessimism. At the same time, the reiterated 2026 outlook implies a need for faster growth beginning in the second quarter, which Brennan views as execution risk, especially given ongoing competitive pressures and recent pricing concessions that weighed on cash flow. With the VWR distribution and Bioscience & Medtech segments still posting organic declines and the path to a more durable upturn not yet fully proven, he maintains a neutral stance, trimming the price target from $10 to $9 while awaiting clearer evidence that operational improvements and market stabilization can translate into sustainable growth. Brennan covers the Healthcare sector, focusing on stocks such as Agilent, Illumina, and Thermo Fisher. According to TipRanks, Brennan has an average return of 13.9% and a 46.49% success rate on recommended stocks. ### Related Stocks - [AVTR.US](https://longbridge.com/en/quote/AVTR.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [A.US](https://longbridge.com/en/quote/A.US.md) - [ILMN.US](https://longbridge.com/en/quote/ILMN.US.md) - [TMO.US](https://longbridge.com/en/quote/TMO.US.md) ## Related News & Research - [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md) - [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md) - [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md) - [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md) - [Coherent Corp. Rocked by Major Insider Stock Move From Company Director](https://longbridge.com/en/news/286343834.md)